PT  - JOURNAL ARTICLE
AU  - Karin S. Walsh
AU  - Pamela L. Wolters
AU  - Brigitte C. Widemann
AU  - Allison A. del Castillo
AU  - Maegan D. Sady
AU  - Tess Inker
AU  - Marie Claire Roderick
AU  - Staci Martin
AU  - Mary Anne Toledo-Tamula
AU  - Kari Struemph
AU  - Iris Paltin
AU  - Victoria Collier
AU  - Kathy Mullin
AU  - Michael J. Fisher
AU  - Roger J. Packer
TI  - Impact of MEK inhibitor therapy on neurocognition in neurofibromatosis type 1
AID  - 10.1101/2020.12.18.20248334
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.18.20248334
4099  - http://medrxiv.org/content/early/2020/12/20/2020.12.18.20248334.short
4100  - http://medrxiv.org/content/early/2020/12/20/2020.12.18.20248334.full
AB  - Objective NF1-associated cognitive impairments carry significant life-long morbidity. The lack of targeted biologic treatments remains a significant unmet need. We examine changes in cognition in patients with NF1 in the first 48 weeks of MEK inhibitor (MEKi) treatment.Methods 59 NF1 patients ages 5-27 on a MEKi clinical trial treating plexiform neurofibroma underwent pre-treatment and follow-up cognitive assessments over 48-weeks of treatment. Performance tasks (Cogstate) and observer-reported functioning (BRIEF) were primary outcomes. Group-level (paired t-tests) and individual-level analyses (reliable change index; RCI) were used.Results Analysis showed statistically significant improvements on BRIEF compared to baseline (24-week BRI: t(58)=3.03, p=.004, d=0.24; 48-week MCI: t(39)=2.70, p=.01, d=0.27). RCI indicated more patients had clinically significant improvement at 48-weeks than expected by chance (Chi Square=11.95, p=.001, OR=6.3). Group-level analyses indicated stable performance on Cogstate (p>.05). RCI statistics showed high proportions of improved working memory (24-weeks Chi Square=8.36, p=.004, OR=4.6 and 48-weeks Chi Square=9.34, p=.004, OR=5.3) but not visual learning/memory. Patients with baseline impairments on BRIEF were more likely to show significant improvement than non-impaired patients (24-weeks 46% v. 8%; Chi Square=9.54, p=.008, OR=9.22; 48-weeks 63% v. 16%; Chi Square=7.50, p=.02, OR=9.0).Interpretation Our data shows no evidence of neurotoxicity in 48-weeks of treatment with a MEKi and a potential clinical signal supporting future research of MEKi as a cognitive intervention.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03962543, NCT02096471, NCT02407405, NCT02124772Funding StatementThis research was supported by the Children's Tumor Foundation, the Gilbert Neurofibromatosis Institute, and in part by the Intramural Research Program of the Center for Cancer Research, NCI, NIH, Bethesda, MD. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institute of Health, under Contract NO 75N91019D00024, Task order NO 75N91019F00129. The content of this publication does not necessarily reflect the views or policies of the department of Health and Human Services, nor does mention of trade names, commercial products, or organizational imply endorsement by the US Government. None of the funding sources had any role in the writing of the manuscript or the decision to submit.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Children's National Hospital IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis data is not currently openly available.